Autonomix Medical, Inc. Common Stock (AMIX) 10-Year Financial Performance & Capital Metrics

AMIX • • Industrial / General

HealthcareMedical DevicesNeurological & Neurostimulation DevicesNeurological Monitoring & Diagnostics

AboutAutonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.Show more

Revenue $0
EBITDA -$11M +4.6%
Net Income -$11M +26.0%
EPS (Diluted) -6.46 +69.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -145.1% +61.1%
ROIC -
Debt/Equity -
Interest Coverage -65.84 +56.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.1x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-18.99%

EPS CAGR

10Y-

5Y-

3Y-

TTM-86.32%

ROCE

10Y Avg-311.15%

5Y Avg-311.15%

3Y Avg-183.61%

Latest-138.54%

Peer Comparison

Neurological Monitoring & Diagnostics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
AMIXAutonomix Medical, Inc. Common Stock	3.59M	0.52	-0.08			-258.98%
CBLLCeriBell, Inc.	847.27M	22.84	-6.74	44.71%	-63.35%	-31.97%	0.11
NMTCNeuroOne Medical Technologies Corporation	45.32M	0.90	-9.99	250.35%	-39.63%	-50.98%	0.04
CLPTClearPoint Neuro, Inc.	435.81M	14.65	-20.93	31.04%	-67.4%	-145.77%	0.14

Profit & Loss

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	13.59M	1.99M	12.03M	11.59M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	13.59M	1.25M	5.25M	6.86M
SG&A % of Revenue	-	-	-	-
Research & Development	4.07K	745K	2.23M	4.72M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	4.56M	0
Operating Income+	-13.59M	-1.99M	-12.03M	-11.59M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.85%	-5.05%	0.04%
EBITDA+	0	-1.99M	-11.95M	-11.4M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-	-5%	0.05%
D&A (Non-Cash Add-back)	13.59M	0	81K	183K
EBIT	-13.59M	-1.99M	-15.35M	-11.23M
Net Interest Income+	-218.09K	0	48K	178K
Interest Income	0	0	127K	354K
Interest Expense	218.09K	0	79K	176K
Other Income/Expense	265.56K	0	-3.4M	178K
Pretax Income+	-13.33M	-1.99M	-15.43M	-11.41M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-13.33M	-1.99M	-15.43M	-11.41M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.85%	-6.75%	0.26%
Net Income (Continuing)	-13.33M	-1.99M	-15.43M	-11.41M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.71	-0.11	-21.09	-6.46
EPS Growth %	-	0.85%	-190.73%	0.69%
EPS (Basic)	-0.71	-0.11	-21.10	-6.46
Diluted Shares Outstanding	18.79M	18.79M	731.31K	1.77M
Basic Shares Outstanding	18.79M	18.79M	731K	1.77M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Total Current Assets+	2.05M	865K	9.39M	9.61M
Cash & Short-Term Investments	2.04M	865K	8.61M	9.14M
Cash Only	2.04M	865K	8.61M	9.14M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	8.73K	0	783K	473K
Total Non-Current Assets+	0	0	16K	197K
Property, Plant & Equipment	0	0	16K	21K
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	176K
Total Assets+	2.05M	865K	9.41M	9.81M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.58%	9.88%	0.04%
Total Current Liabilities+	93.24K	221K	777K	1.71M
Accounts Payable	91.62K	173K	492K	676K
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	0	0	0
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	1.62K	0	0	0
Current Ratio	22.02x	3.91x	12.09x	5.63x
Quick Ratio	22.02x	3.91x	12.09x	5.63x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	0	1M	0
Long-Term Debt	0	0	1M	0
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	93.24K	221K	1.78M	1.71M
Total Debt+	0	0	1M	0
Net Debt	-2.04M	-865K	-7.61M	-9.14M
Debt / Equity	-	-	0.13x	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-62.33x	-	-152.28x	-65.84x
Total Equity+	1.96M	644K	7.63M	8.1M
Equity Growth %	-	-0.67%	10.84%	0.06%
Book Value per Share	0.10	0.03	10.43	4.59
Total Shareholders' Equity	1.96M	644K	7.63M	8.1M
Common Stock	12K	12K	19K	2K
Retained Earnings	-21.55M	-23.54M	-38.97M	-50.38M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations+	-387.31K	-1.85M	-6.65M	-8.26M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-3.79%	-2.58%	-0.24%
Net Income	-13.33M	-1.99M	-15.43M	-11.41M
Depreciation & Amortization	0	0	81K	183K
Stock-Based Compensation	0	0	618	1.63M
Deferred Taxes	0	0	0	0
Other Non-Cash Items	12.74M	0	8.62M	101K
Working Capital Changes	204.41K	136.08K	79K	1.24M
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	87.08K	80.91K	320K	184K
Cash from Investing+	0	0	-19K	-14K
Capital Expenditures	0	0	-19K	-14K
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	2.43M	675K	14.41M	8.8M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	0	-1.3M	-1.23M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-387.31K	-1.85M	-6.67M	-8.27M
FCF Margin %	-	-	-	-
FCF Growth %	-	-3.79%	-2.6%	-0.24%
FCF per Share	-0.02	-0.10	-9.12	-4.68
FCF Conversion (FCF/Net Income)	0.03x	0.93x	0.43x	0.72x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2022	2023	2024	2025
Return on Equity (ROE)	-680.21%	-152.87%	-372.97%	-145.1%
Debt / Equity	-	-	0.13x	-
Interest Coverage	-62.33x	-	-152.28x	-65.84x
FCF Conversion	0.03x	0.93x	0.43x	0.72x

Frequently Asked Questions

Growth & Financials

Autonomix Medical, Inc. Common Stock (AMIX) grew revenue by 0.0% over the past year. Growth has been modest.

Autonomix Medical, Inc. Common Stock (AMIX) reported a net loss of $16.7M for fiscal year 2025.

Dividend & Returns

Autonomix Medical, Inc. Common Stock (AMIX) has a return on equity (ROE) of -145.1%. Negative ROE indicates the company is unprofitable.

Autonomix Medical, Inc. Common Stock (AMIX) had negative free cash flow of $10.1M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener